Neurocrine Biosciences Inc (NBIX) Stock Price, Trades & News

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Financial Strength

8/10

Name	Current	Vs Industry	Vs History
Cash-To-Debt	2.11
Equity-to-Asset	0.69
Debt-to-Equity	0.18
Debt-to-EBITDA	0.8
Interest Coverage	N/A	N/A	N/A
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	8.03	Distress Grey Safe
Beneish M-Score	-2.55	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	25.2
	3-Year EBITDA Growth Rate	63.5
	3-Year EPS without NRI Growth Rate	49.4
	3-Year FCF Growth Rate	31.2
	3-Year Book Growth Rate	21.6
	Future 3-5Y Total Revenue Growth Rate Estimate	13.82

Momentum Rank

2/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	65.55
	9-Day RSI	62.99
	14-Day RSI	62.53
	3-1 Month Momentum %	14.97
	6-1 Month Momentum %	-9.88
	12-1 Month Momentum %	-12.2

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	3.13
	Quick Ratio	3.02
	Cash Ratio	1.8
	Days Inventory	494.85
	Days Sales Outstanding	72.47
	Days Payable	1043.27

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-1.6
	Shareholder Yield %	1.34

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	98.52
	Operating Margin %	20.78
	Net Margin %	12.68
	EBITDA Margin %	23.19
	FCF Margin %	20.4
	ROE %	12
	ROA %	8.63
	ROIC %	14.51
	3-Year ROIIC %	19.07
	ROC (Joel Greenblatt) %	85.49
	ROCE %	17.53
	Years of Profitability over Past 10-Year	7
	Moat score	6
	Tariff score	7

GF Value Rank

8/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	43.86
	Forward PE Ratio	32.95
	PE Ratio without NRI	26.81
	Shiller PE Ratio	148.74
	Price-to-Owner-Earnings	72.79
	PEG Ratio	0.58
	PS Ratio	5.53
	PB Ratio	5.05
	Price-to-Tangible-Book	5.12
	Price-to-Free-Cash-Flow	27.14
	Price-to-Operating-Cash-Flow	25.23
	EV-to-EBIT	22.92
	EV-to-Forward-EBIT	18.51
	EV-to-EBITDA	21.75
	EV-to-Forward-EBITDA	18.83
	EV-to-Revenue	5.05
	EV-to-Forward-Revenue	4.51
	EV-to-FCF	24.73
	Price-to-GF-Value	0.77
	Price-to-Projected-FCF	2.04
	Price-to-Median-PS-Value	0.48
	Price-to-Peter-Lynch-Fair-Value	1.07
	Price-to-Graham-Number	2.47
	Price-to-Net-Current-Asset-Value	26.35
	Earnings Yield (Greenblatt) %	4.36
	FCF Yield %	3.84
	Forward Rate of Return (Yacktman) %	22.58

GF Value: $167.03

NBIX

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with NBIX. Try a 7-Day Free Trial to check it out.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.